Cardiff Oncology (CRDF) Enterprise Value (2016 - 2025)
Cardiff Oncology (CRDF) has disclosed Enterprise Value for 15 consecutive years, with -$58.3 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 36.45% to -$58.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$58.3 million through Dec 2025, up 36.45% year-over-year, with the annual reading at -$58.3 million for FY2025, 36.45% up from the prior year.
- Enterprise Value hit -$58.3 million in Q4 2025 for Cardiff Oncology, up from -$60.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$57.7 million in Q3 2024 to a low of -$140.8 million in Q4 2021.
- Historically, Enterprise Value has averaged -$100.8 million across 5 years, with a median of -$101.1 million in 2022.
- Biggest five-year swings in Enterprise Value: crashed 1253.71% in 2021 and later skyrocketed 36.45% in 2025.
- Year by year, Enterprise Value stood at -$140.8 million in 2021, then rose by 25.25% to -$105.3 million in 2022, then increased by 28.92% to -$74.8 million in 2023, then fell by 22.62% to -$91.7 million in 2024, then surged by 36.45% to -$58.3 million in 2025.
- Business Quant data shows Enterprise Value for CRDF at -$58.3 million in Q4 2025, -$60.6 million in Q3 2025, and -$131.2 million in Q2 2025.